Navigation Links
Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR
Date:10/8/2008

ams; our planned Phase 2 clinical studies and the ability of those studies to successfully evaluate HspE7 as a potential treatment for CIN 1 and CIN 2/3; the structure and location of our planned Phase 2 trials; completion of the second protocol for CIN 1; potential uses for Poly-ICR; our ability to advance Poly-ICR resulting in revenue generation and internal development; the ability of Poly-ICR to provide us with near-term revenue opportunity; the development of Poly-ICR for treatment of GW and actinic keratosis; completion of development activities and the filing of an IND application in connection with Poly-ICR; finalizing manufacturing and formulation protocols and filing an IND in connection with Hsp 6/11; execution of our corporate restructuring as planned; our ability to retain key personnel; and our plan to expand corporate development efforts and the potential results of such efforts.

Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments to be materially different from results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, the possibility that our planned corporate restructuring will not have the anticipated affect; that we will not succeed in forming strategic alliances and, if we do, the possibility that such alliances will not allow us to realize the greatest value for our programs; that we will not commence Phase 2 clinical studies as planned and, if we do, that such studies will not support the use of HspE7 as a treatment for CIN 1 or CIN 2/3; that we will not complete the second protocol for the CIN 1 indication; that Poly-IRC will not be useful as a broad immune stimulatory agent or vaccine adjuvant; that we will not be able to advance Poly-ICR to generate revenue or for internal development; that Poly-ICR will not provide us with near-term reve
'/>"/>

SOURCE Nventa Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa announces publication of HspE7 data
3. Nventas CEO to present at two upcoming investor conferences
4. Nventa updates progress of cervical dysplasia trial with new HspE7
5. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
6. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
7. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
8. Nventa Appoints John Varian to Board of Directors
9. Nventa Appoints Gordon H. Busenbark to Board of Directors
10. CardioDynamics Provides 2007 Shareholder Meeting Update
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... October 20, 2014 Local veterinary surgeon, ... an investigational study of donor stem cells for dogs ... cell therapy and has performed clinical stem cell therapy ... is to determine if a single injection of donor ... can help reduce pain and inflammation in the treated ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 The ... bromine market in Asia-Pacific with analysis and forecast ... the Asia Pacific Bromine Market report, to get ... also provides a glimpse of the segmentation in ... various tables and figures. , http://www.micromarketmonitor.com/market/asia-pacific-bromine-6741503144.html ...
(Date:10/19/2014)... The Asian Orthopedic braces and support systems ... analysis and forecast of revenue. The Orthopedic braces and support ... $416.5 million by 2018, at a developing CAGR of 4.4% ... the Asian Orthopedic braces and support systems market, to get ... a glimpse of the segmentation of orthopedic braces and support ...
(Date:10/18/2014)... 2014 The Asia-Pacific Bio-based Advanced ... the bio-based advanced phase change material market in ... Browse through the TOC of the Asia-Pacific Bio-based ... an idea of the in-depth analysis provided. This ... the Asia-Pacific bio-based advanced phase change material market, ...
Breaking Biology Technology:Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 2The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 4The Asia-Pacific Bio-based Advanced Phase Change Materials Market is estimated to grow to $39.8 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bio-based Advanced Phase Change Materials Market is estimated to grow to $39.8 million by 2018 - New Report by MicroMarket Monitor 3The Asia-Pacific Bio-based Advanced Phase Change Materials Market is estimated to grow to $39.8 million by 2018 - New Report by MicroMarket Monitor 4
... 22, 2011 With the intent to create a ... Akron, the Austen BioInnovation Institute in Akron (ABIA) has ... "Healthier by Design: Creating Accountable Care Communities" held today. ... and wellness thought-leaders, the strategic discussion is the first ...
... BASEL, Switzerland, June 22, 2011 The Roche manuscript: ... Production of Bispecific IgG Antibodies" has been published in ... of the USA (PNAS). Corresponding authors are ... at Penzberg, and Christian Klein, Head of Oncology Programs, ...
... ,   Crescendo ... Roe as Chief Business Officer. Matthew joins,Crescendo from ... & Licensing. During a 23-year career ... acquisition, divestment, and sales,and marketing, and saw the ...
Cached Biology Technology:Austen BioInnovation Institute in Akron Begins Work on Roadmap for First U.S. Accountable Care Community 2Austen BioInnovation Institute in Akron Begins Work on Roadmap for First U.S. Accountable Care Community 3Proceedings of the National Academy of Sciences (PNAS) Publishes Roche Manuscript on Production of Bispecific IgG Antibodies 2Crescendo Biologics Appoints Matthew Roe as Chief Business Officer 2
(Date:10/14/2014)... N.Y. – Scientists have sequenced the house fly genome ... one might expect from an insect that thrives in ... published Oct. 14 in the journal Genome Biology ... biology and of how flies quickly adapt to resist ... Adult house flies (Musca domestica) carry and transmit more ...
(Date:10/14/2014)... team has discovered a new kind of stem cell that ... lines liver blood vessels, according to a study published today ... of such a cell type contradicts current theory on how ... hold clues to origins of, and future treatment for, liver ... cell into a complex being made up of more than ...
(Date:10/14/2014)... October 14, 2014 – Scientists from The Scripps Research ... National Institutes of Health (NIH) to lead an investigation ... fever disease in Africa. The study aims to understand ... patients die, while others survive the inflection. , ... basic mechanism of how Lassa fever virus causes disease ...
Breaking Biology News(10 mins):House fly genome reveals expanded immune system 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 3Scripps Research Institute team receives $6.6 million to investigate deadly Lassa virus 2
... will leave the lab this summer to apply ... skills at workshops held around the country by ... in science majors grows, college-level science teaching must ... inquiry-based learning, according to MSU plant biology professor ...
... has patented an improved microscopy method for measuring the ... create new pharmaceuticals that are a better match for ... Aberration Correction (DAC) microscopy, measures distances at the molecular ... microscopy. A special feature of the new method, ...
... Feb. 6, 2009 Complete Genomics, Inc. released proof-of-concept ... the first time yesterday evening. The analysis results were ... and CEO, during his presentation at the annual Advances ... Marco Island Marriott Beach Resort, Marco Island, Fla. ...
Cached Biology News:NSF-funded workshops help young researchers teach science 2Measuring molecules to improve drug design 2Complete Genomics releases proof-of-concept data for its sequencing technology for the first time 2Complete Genomics releases proof-of-concept data for its sequencing technology for the first time 3
The SVT3-2 diverter valve is a 3-port, 2-position valve for use with the BioLogic DuoFlow system....
... for 2-D separations. The cell has a six-gel ... xi multi-cell can be customized for several parameters: ... cooling system. The PROTEAN II xi multi-cell can ... multi-cell for a wider format that accommodates 17 ...
... 16 cm, is used for vertical slab gel ... gels. The cell is supplied without spacers and ... with gaskets, lower buffer chamber, lid with cables, ... upper buffer dam, casting stand with gaskets, leveling ...
CleanCut agarose is used to prepare genomic DNA plugs for use in pulsed field gel electrophoresis (PFGE) applications. Supplied as a 12 ml solution of 2% agarose....
Biology Products: